TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31415381

Group type: EXPERIMENTAL
Intervention: Qingzhong (TDF) 300mg once daily for 48 weeks
Number of subjects: 330

Group type: COMPARATOR
Intervention: Viread (TDF) 300mg once daily for 48 weeks
Number of subjects: 330
Study: 27741030

Group type: EXPERIMENTAL
Intervention: Self-expandable metal stents (SEMS)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Plastic stents
Number of subjects: 219
Study: 26044169

Group type: EXPERIMENTAL
Intervention: Intranasal GSK2245035 doses <100 ng
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal GSK2245035 at 20 ng
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat intranasal GSK2245035 administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal GSK2245035
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23432466

Group type: EXPERIMENTAL
Intervention: NRTI-sparing regimens (e.g., raltegravir plus darunavir/ritonavir)
Number of subjects: 689

Group type: COMPARATOR
Intervention: NRTI-based regimens (e.g., tenofovir DF/emtricitabine plus darunavir/ritonavir)
Number of subjects: 689
Study: 22108937

Group type: EXPERIMENTAL
Intervention: Adenosine 400 μmol l(‐1) in antegrade cardioplegia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo in antegrade cardioplegia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Adenosine 400 μmol l(‐1) in retrograde cardioplegia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo in retrograde cardioplegia
Number of subjects: 80
Study: 19158228

Group type: EXPERIMENTAL
Intervention: Moderate-protein diet (PRO) with 1.6 g/kg/d protein and <170 g/d carbohydrates
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Moderate-protein diet (PRO)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional high-carbohydrate diet (CHO)
Number of subjects: 130
Study: 17451579

Group type: EXPERIMENTAL
Intervention: 5 U of BTX (BOTOX Cosmetic, Allergan Inc.)
Number of subjects: 20
Study: 15169614

Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 0
Study: 11289347

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethylstarch (200 kDa, 0.60‐0.66 substitution)
Number of subjects: 129

Group type: COMPARATOR
Intervention: 3% fluid‐modified gelatin
Number of subjects: 129
Study: 9923089

Group type: EXPERIMENTAL
Intervention: Meal-stimulated plasma CCK bioactivity in CP patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Meal-stimulated plasma CCK bioactivity in healthy controls
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of plasma CCK bioactivity between CP patients and healthy controls
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Correlation between impairment of pancreatic exocrine function and plasma CCK bioactivity
Number of subjects: 24
Study: 8149056

Group type: EXPERIMENTAL
Intervention: Early mobilisation (first postoperative day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late mobilisation (tenth postoperative day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: History of oral steroid therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severity of tissue damage (undermining of skin margins, damage to fascia, exposure of periosteum)
Number of subjects: 0
Study: 2905256

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg once daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: roxatidine acetate 75 mg twice daily
Number of subjects: 300
Study: 29588293

Group type: EXPERIMENTAL
Intervention: Self-management intervention assisted by a promotora (Hispanic community health worker)
Number of subjects: 251
Study: 26695507

Group type: EXPERIMENTAL
Intervention: Experienced Caregivers Helping Others intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard inpatient care)
Number of subjects: 0
Study: 25087325

Group type: EXPERIMENTAL
Intervention: Computer-based simulation
Number of subjects: 213

Group type: COMPARATOR
Intervention: Instructor-led resuscitation training-only group
Number of subjects: 213
Study: 23770179

Group type: EXPERIMENTAL
Intervention: ETC-1002 40 mg
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: ETC-1002 80 mg
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: ETC-1002 120 mg
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 20185616

Group type: EXPERIMENTAL
Intervention: 30 hours of robotic-assisted therapy combined with 30 hours of therapist-supervised repetitive task practice (RTP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 60 hours of therapist-supervised repetitive task practice (RTP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups (combined therapy and RTP-only)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined therapy group
Number of subjects: 17

Group type: COMPARATOR
Intervention: RTP-only group
Number of subjects: 17
Study: 18286595

Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine (LAC) 20-50 mg/kg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 16422828

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14583175

Group type: EXPERIMENTAL
Intervention: Intensive glycemic treatment aiming at normal HbA1c levels
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Standard arm with usual, improved glycemic control
Number of subjects: 1700
Study: 10555125

Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2 without G-CSF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2 with G-CSF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Epirubicin pharmacokinetics
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2
Number of subjects: 35
Study: 8724309

Group type: EXPERIMENTAL
Intervention: IVIG (intravenous immunoglobulin) at a dose between 1.5 and 2.0 g/kg/infusion (100 g maximum) bimonthly for the first 2 months, then monthly for up to 6 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IVIG (intravenous immunoglobulin) continued in the double-blind phase
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IVIG (intravenous immunoglobulin)
Number of subjects: 25
Study: 1761450

Group type: EXPERIMENTAL
Intervention: Tobramycin dosage regimens determined by a computerized pharmacokinetic predictive program (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tobramycin dosage regimens decided by clinicians based on pre-existing protocols (Group A)
Number of subjects: 0
Study: 6750609

Group type: EXPERIMENTAL
Intervention: Local hyperthermia treatment (three 30-min insufflations of humidified air at 43 degrees C at a 2-hr interval)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 95
Study: 30070706

Group type: EXPERIMENTAL
Intervention: 20% sucrose solution applied 4 times per day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20% sucrose solution applied 8 times per day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (0× sucrose treatment)
Number of subjects: 10
Study: 27913933

Group type: EXPERIMENTAL
Intervention: Fatigue Reduction Diet (FRD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: General Health Curriculum (GHC)
Number of subjects: 30
Study: 26822022

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for 12 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for 16 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for 12 weeks in patients with cirrhosis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for 16 weeks in patients with cirrhosis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for treatment-experienced patients with cirrhosis
Number of subjects: 50
Study: 25098442

Group type: EXPERIMENTAL
Intervention: Printed Educational Materials (PEMs)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 437
Study: 22549401

Group type: EXPERIMENTAL
Intervention: Routine training
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Computer training
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Augmented training
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Ongoing consultation after training
Number of subjects: 115
Study: 19189088

Group type: EXPERIMENTAL
Intervention: Oral administration of bromazepam
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nasogastric administration of bromazepam
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral administration of omeprazole
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nasogastric administration of omeprazole
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral administration of paracetamol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nasogastric administration of paracetamol
Number of subjects: 8
Study: 17399725

Group type: EXPERIMENTAL
Intervention: Physical activity inducing slopes 1000 m/s(3)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Impacts with slopes <1000 m/s(3)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Impacts with slopes 1500 m/s(3) or areas 4m/s
Number of subjects: 64
Study: 15389347

Group type: EXPERIMENTAL
Intervention: Losartan (50 to 100 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11464229

Group type: EXPERIMENTAL
Intervention: Dietary modification with increased use of vitamin E-rich foods
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Supplementation with 200 IU of vitamin E
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 9882032

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg before breakfast (qAM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg before dinner (qPM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg before breakfast and dinner (b.d.)
Number of subjects: 18
Study: 7924325

Group type: EXPERIMENTAL
Intervention: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h + transdermal estradiol at 50 micrograms/24h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h + transdermal estradiol at 100 micrograms/24h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vaginal rings releasing levonorgestrel (L‐NOG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vaginal rings releasing levonorgestrel (L‐NOG) + estradiol (50 or 100 micrograms/24h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Estradiol treatment
Number of subjects: 24
Study: 2803900

Group type: EXPERIMENTAL
Intervention: Diphtheria/tetanus vaccine
Number of subjects: 180
Study: 1169086

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (P.G.V.) without drainage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Selective vagotomy and gastrojejunostomy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (P.G.V.) with gastrojejunostomy
Number of subjects: 100
Study: 29035844

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 643

Group type: COMPARATOR
Intervention: Guided femoral access (fluoroscopy, micropuncture, ultrasound)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Non-guided femoral access
Number of subjects: 643
Study: 27875518

Group type: EXPERIMENTAL
Intervention: Enhanced reminder letter
Number of subjects: 168480

Group type: COMPARATOR
Intervention: Usual reminder letter
Number of subjects: 168480
Study: 23835594

Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise (alternating 60s at 100% VO(2peak) and 240s at 50% VO(2peak))
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Very-high-intensity intermittent exercise (alternating 15s at 170% VO(2peak) and 60s at 32% VO(2peak))
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Very-high-intensity intermittent exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: High-intensity intermittent exercise and Very-high-intensity intermittent exercise
Number of subjects: 17
Study: 20888653

Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 602
Study: 20856152

Group type: EXPERIMENTAL
Intervention: FDG‐PET
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional Work-Up (CWU)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: NMB analysis
Number of subjects: 150
Study: 18818460

Group type: EXPERIMENTAL
Intervention: SRP plus minocycline
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 30
Study: 15363656

Group type: EXPERIMENTAL
Intervention: 100 mg Pycnogenol for 12 weeks
Number of subjects: 77
Study: 11180035

Group type: EXPERIMENTAL
Intervention: Oral tacrolimus (5 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravenous tacrolimus (0.015 mg/kg)
Number of subjects: 34
Study: 9844958

Group type: EXPERIMENTAL
Intervention: Depressive patients (mI/Cr ratio in left frontal lobe: 0.43 +/- 0.06)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy subjects (mI/Cr ratio in left frontal lobe: 0.46 +/- 0.07)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Depressive patients (mI/Cr ratio in right frontal lobe: 0.46 +/- 0.08)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy subjects (mI/Cr ratio in right frontal lobe: 0.48 +/- 0.06)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Age matched pairs analysis of depressed patients (mI/Cr ratio in right frontal lobe: 0.40 +/- 0.05)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Age matched pairs analysis of healthy subjects (mI/Cr ratio in right frontal lobe: 0.45 +/- 0.06)
Number of subjects: 22
Study: 8127015

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.21 +/- 0.02 microgram/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no calcitriol treatment)
Number of subjects: 21
Study: 2597240

Group type: EXPERIMENTAL
Intervention: Jumping rope
Number of subjects: 30

Group type: COMPARATOR
Intervention: Jumping in place (without a rope)
Number of subjects: 30
Study: 15867103

Group type: EXPERIMENTAL
Intervention: Supported Employment (SE) program
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Control group (services as usual)
Number of subjects: 1273
Study: 31828857

Group type: EXPERIMENTAL
Intervention: 600mg Trigonella foenum‐graecum per day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29629505

Group type: EXPERIMENTAL
Intervention: Marijuana dispensary websites
Number of subjects: 97
Study: 28657604

Group type: EXPERIMENTAL
Intervention: RESMENA dietary group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fruit fiber consumption (≥8.8 g/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: AHA dietary group
Number of subjects: 70
Study: 25279689

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (treadmill training three times per week for 3 months) + vitamin B6 and Ca supplements
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vitamin B6 and Ca supplements (control group)
Number of subjects: 30
Study: 23865727

Group type: EXPERIMENTAL
Intervention: Zabofloxacin hydrochloride 400 mg capsule (DW224a)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Zabofloxacin aspartate 488 mg tablet (DW224aa)
Number of subjects: 32
Study: 22096523

Group type: EXPERIMENTAL
Intervention: Internet-based self-management program involving weekly online monitoring of asthma control with self-treatment advice, remote Web communications, and Internet-based information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19338148

Group type: EXPERIMENTAL
Intervention: Jianpi Wenshen Recipe (JPWS) alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Jianpi Wenshen Recipe (JPWS) plus chemotherapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 51
Study: 16782097

Group type: EXPERIMENTAL
Intervention: recombinant human FSH (rhFSH) at high doses (300 IU on alternate days) for a period of >or=4 months
Number of subjects: 30
Study: 15220503

Group type: EXPERIMENTAL
Intervention: RF introducer with handheld system
Number of subjects: 99

Group type: COMPARATOR
Intervention: Handheld system alone (control group)
Number of subjects: 99
Study: 11252459

Group type: EXPERIMENTAL
Intervention: Knee brace for three weeks postoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: No knee brace (rehabilitated without the use of a brace)
Number of subjects: 50
Study: 9250802

Group type: EXPERIMENTAL
Intervention: Presence of fever, spleen enlargement, anemia, leukopenia, poor performance status, and poor histologic subgroups
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Fever, spleen involvement, leukopenia, and poor histologic subgroups
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Absence of fever
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Absence of all four significant factors (fever, spleen involvement, leukopenia, poor histologic subgroups)
Number of subjects: 130
Study: 8496218

Group type: EXPERIMENTAL
Intervention: Anatomical reduction
Number of subjects: 127

Group type: COMPARATOR
Intervention: Medial displacement osteotomy
Number of subjects: 127
Study: 3327354

Group type: EXPERIMENTAL
Intervention: Penicillin G
Number of subjects: 457

Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 457
Study: 27673505

Group type: EXPERIMENTAL
Intervention: Naloxone (0.25 μg/kg/h)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27031850

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with chemotherapy
Number of subjects: 774

Group type: COMPARATOR
Intervention: Placebo in combination with chemotherapy
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 774
Study: 24938769

Group type: EXPERIMENTAL
Intervention: Case management care in addition to standard emergency care (1 to 3 times during their stay and after 1, 3, and 5 months)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard emergency care only
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Case management care
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard emergency care
Number of subjects: 250
Study: 22008871

Group type: EXPERIMENTAL
Intervention: Semont's liberatory maneuver (SLM)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 342
Study: 20463113

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 18354844

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 2113

Group type: EXPERIMENTAL
Intervention: Combination of natalizumab and interferon beta
Number of subjects: 2113

Group type: COMPARATOR
Intervention: Interferon beta
Number of subjects: 2113
Study: 15355747

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COX-2 inhibitors
Number of subjects: 0
Study: 11528361

Group type: EXPERIMENTAL
Intervention: Oral E2 valerate (2 mg) + cyproterone acetate (1 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Transdermal E2 (1.5 mg) + oral medroxyprogesterone acetate (5 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study: 9415511

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8119607

Group type: EXPERIMENTAL
Intervention: Fetal vibroacoustic stimulation (5 seconds, 75 Hz frequency, 74 dB intensity)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard nonstress test
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fetal vibroacoustic stimulation
Number of subjects: 100
Study: 3819804

Group type: EXPERIMENTAL
Intervention: High-dose FAC chemotherapy (100% to 260% higher than standard FAC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard-dose FAC chemotherapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High-dose FAC chemotherapy
Number of subjects: 59
Study: 30899530

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 µg/day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 29989857

Group type: EXPERIMENTAL
Intervention: Intensity‐modulated radiation therapy (IMRT)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard four‐field radiation therapy (RT)
Number of subjects: 278
Study: 26620248

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once a day
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 25179871

Group type: EXPERIMENTAL
Intervention: Peer-led intervention focused on colorectal cancer screening, physical activity, and multi-vitamin intake
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Peer-led intervention
Number of subjects: 692
Study: 22894573

Group type: EXPERIMENTAL
Intervention: Ocriplasmin (125 μg)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 21158971

Group type: EXPERIMENTAL
Intervention: Healthy Foods North (HFN) intervention programme implemented over 12 months, combining behaviour change and environmental strategies.
Number of subjects: 0
Study: 17362050

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy approaches
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Newer cytotoxic chemotherapies and biological agents
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 40
Study: 15671706

Group type: EXPERIMENTAL
Intervention: Tailored mail intervention
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Tailored mail plus telephone intervention
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Tailored telephone intervention
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Tailored telephone and mail intervention
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1044